Profile data is unavailable for this security.
About the company
Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the research, development and commercialization of immunotherapies to treat cancer. The Company’s immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor immunologic response and enhance outcomes for patients with cancer. Casdozokitug is an IL-27 antagonistic antibody, which is being evaluated in two ongoing clinical studies: a Phase I/II study in advanced solid tumors and a Phase II study in hepatocellular carcinoma. CHS-114 is a highly selective, cytolytic anti-CCR8 antibody, which is in a Phase I study in patients with advanced solid tumors. CHS-1000 is a preclinical candidate targeting immune-suppressive mechanisms via the pathway ILT4. It markets LOQTORZI (toripalimab-tpzi), a PD-1 inhibitor, and UDENYCA (pegfilgrastim-cbqv), a biosimilar of Neulasta.
- Revenue in USD (TTM)304.34m
- Net income in USD-450.00k
- Incorporated2010
- Employees235.00
- LocationCoherus BioSciences IncC/O DENNIS M. LANFEAR201 REDWOOD SHORES PARKWAY, SUITE 200REDWOOD CITY 94065United StatesUSA
- Phone+1 (650) 649-3530
- Fax+1 (302) 655-5049
- Websitehttps://www.coherus.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chimerix Inc | 159.00k | -83.59m | 89.25m | 72.00 | -- | 0.6573 | -- | 561.34 | -0.9351 | -0.9351 | 0.0018 | 1.51 | 0.0008 | -- | 1.92 | 2,208.33 | -43.54 | -30.45 | -48.29 | -34.09 | 2.52 | -- | -52,574.84 | -442.93 | -- | -- | 0.00 | -- | -99.04 | -46.24 | -147.68 | -- | -13.24 | -- |
| Monopar Therapeutics Inc | 0.00 | -6.47m | 91.04m | 10.00 | -- | 12.29 | -- | -- | -1.99 | -1.99 | 0.00 | 1.40 | 0.00 | -- | -- | 0.00 | -88.32 | -54.07 | -112.04 | -60.60 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 20.10 | -- | -- | -- |
| Citius Oncology Inc | 0.00 | 1.93m | 93.41m | -- | 5.41 | 0.189 | 48.31 | -- | 0.242 | 0.242 | 0.00 | 6.93 | 0.00 | -- | -- | -- | 3.25 | -- | 3.35 | -- | -- | -- | -- | -- | -- | -- | 0.036 | -- | -- | -- | 535.30 | -- | -- | -- |
| Werewolf Therapeutics Inc | 3.39m | -62.12m | 93.96m | 45.00 | -- | 1.05 | -- | 27.75 | -1.50 | -1.50 | 0.0819 | 2.04 | 0.0214 | -- | 1.06 | 72,042.55 | -39.26 | -- | -42.91 | -- | -- | -- | -1,834.55 | -- | -- | -- | 0.2228 | -- | 21.60 | -- | 30.56 | -- | -- | -- |
| Oramed Pharmaceuticals, Inc. | 0.00 | 20.86m | 94.33m | 15.00 | 4.68 | 0.5369 | 4.50 | -- | 0.4999 | 0.4999 | 0.00 | 4.36 | 0.00 | -- | -- | 0.00 | 12.19 | -- | 12.29 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -50.43 | -- | 115.11 | -- | -- | -- |
| MDxHealth SA | 80.74m | -40.80m | 94.54m | 300.00 | -- | -- | -- | 1.17 | -1.54 | -1.54 | 3.06 | -0.3229 | 0.5906 | 9.39 | 7.49 | 269,136.70 | -29.85 | -51.62 | -43.63 | -64.72 | 62.64 | 50.88 | -50.54 | -117.64 | 0.8252 | -1.74 | 1.18 | -- | 89.43 | 19.84 | 2.14 | -- | 30.13 | -- |
| Cidara Therapeutics Inc | 18.86m | -123.53m | 94.78m | 69.00 | -- | 0.8197 | -- | 5.03 | -26.06 | -25.94 | 3.74 | 16.41 | 0.167 | -- | 8.28 | 273,304.30 | -109.42 | -65.23 | -169.41 | -154.37 | 87.21 | -- | -655.07 | -100.61 | -- | -- | 0.0055 | -- | -0.8425 | -- | 31.72 | -- | 23.33 | -- |
| Coherus Biosciences Inc | 304.34m | -450.00k | 94.88m | 235.00 | -- | -- | 19.54 | 0.3118 | -0.0892 | -0.0892 | 2.60 | -0.7636 | 0.5591 | 2.94 | 1.58 | 994,575.20 | -0.0827 | -21.43 | -0.1626 | -29.32 | 44.71 | 79.01 | -0.1479 | -36.56 | 1.09 | -3.92 | 1.50 | -- | 21.89 | -- | 18.46 | -- | -18.37 | -- |
| Ikena Oncology Inc | 659.00k | -59.60m | 96.14m | 18.00 | -- | 0.6327 | -- | 145.89 | -1.24 | -1.24 | 0.0137 | 2.78 | 0.0036 | -- | -- | 15,325.58 | -32.72 | -29.72 | -35.50 | -34.62 | -- | -- | -9,043.85 | -294.90 | -- | -- | 0.00 | -- | -41.35 | 56.05 | 0.8711 | -- | 6.30 | -- |
| CervoMed Inc | 9.65m | -5.04m | 97.64m | 8.00 | -- | 1.95 | -- | 10.11 | -0.4796 | -0.4796 | 1.55 | 6.06 | 0.2803 | -- | -- | 1,206,660.00 | -14.64 | -53.67 | -15.71 | -58.89 | -- | -- | -52.24 | -949.54 | -- | -- | 0.00 | -- | -- | -- | 86.07 | -- | -- | -- |
| Hillevax Inc | 0.00 | -150.28m | 98.62m | 90.00 | -- | 0.5315 | -- | -- | -3.09 | -3.09 | 0.00 | 3.73 | 0.00 | -- | -- | 0.00 | -51.15 | -- | -54.17 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.68 | -- | -- | -- |
| Adicet Bio Inc | 0.00 | -117.88m | 98.88m | 143.00 | -- | 0.4675 | -- | -- | -1.70 | -1.70 | 0.00 | 2.57 | 0.00 | -- | -- | 0.00 | -49.20 | -37.03 | -53.58 | -40.28 | -- | -- | -- | -748.46 | -- | -- | 0.00 | -- | -100.00 | -- | -104.41 | -- | 65.27 | -- |
| Armata Pharmaceuticals Inc | 3.72m | -67.04m | 99.50m | 66.00 | -- | -- | -- | 26.76 | -1.95 | -1.95 | 0.0893 | -1.28 | 0.0355 | -- | 0.7532 | 56,348.48 | -64.00 | -59.78 | -385.50 | -72.70 | -- | -- | -1,802.72 | -1,113.72 | -- | -1.99 | 1.71 | -- | -17.77 | -- | -87.03 | -- | 184.10 | -- |
| Relmada Therapeutics Inc | 0.00 | -86.49m | 99.57m | 20.00 | -- | 2.09 | -- | -- | -2.87 | -2.87 | 0.00 | 1.58 | 0.00 | -- | -- | 0.00 | -104.91 | -- | -116.60 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 37.09 | -- | -- | -- |
| Milestone Pharmaceuticals Inc | 0.00 | -48.41m | 99.61m | 47.00 | -- | 3.12 | -- | -- | -1.01 | -1.01 | 0.00 | 0.6003 | 0.00 | -- | -- | 0.00 | -51.98 | -48.44 | -55.36 | -51.56 | -- | -- | -- | -1,267.25 | -- | -- | 0.6171 | -- | -80.00 | -- | -2.22 | -- | 86.23 | -- |
| X4 Pharmaceuticals Inc | 563.00k | 17.63m | 99.77m | 93.00 | 6.91 | 1.05 | 5.53 | 177.21 | 0.0857 | 0.0857 | 0.0028 | 0.5616 | 0.0029 | -- | 0.6726 | 6,053.76 | 9.18 | -61.53 | 10.59 | -69.20 | 52.40 | -- | 3,131.79 | -13,288.93 | 6.04 | -- | 0.4427 | -- | -- | -- | -4.93 | -- | 12.03 | -- |
Data as of Nov 13 2024. Currency figures normalised to Coherus BioSciences Inc's reporting currency: US Dollar USD
42.47%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Jun 2024 | 10.49m | 9.10% |
| Rubric Capital Management LPas of 30 Jun 2024 | 10.40m | 9.03% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 9.29m | 8.06% |
| Temasek Holdings Pte Ltd. (Investment Management)as of 22 Jul 2024 | 5.54m | 4.81% |
| Citadel Advisors LLCas of 30 Jun 2024 | 2.83m | 2.45% |
| Geode Capital Management LLCas of 30 Jun 2024 | 2.38m | 2.07% |
| Barclays Bank Plc (Private Banking)as of 30 Jun 2024 | 2.19m | 1.90% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 2.01m | 1.75% |
| C WorldWide Asset Management Fondsm�glerselskab A/Sas of 30 Sep 2024 | 1.93m | 1.67% |
| Goldman Sachs & Co. LLC (Private Banking)as of 30 Jun 2024 | 1.88m | 1.63% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
